Apel Daniel Joseph reported ARWR

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0002081169-26-000002

Machine-readable

Structured copy

Timestamps

Event (reported)

Jan 6, 2026

Published

Jan 8, 2026

Ingested by INSIDER

Nov 5, 04:23 UTC

Last re-read

Nov 5, 04:23 UTC

Extracted facts

Filer

Apel Daniel Joseph

Role

Chief Financial Officer

Transaction

Grant or awardAs filed: “A”

Asset

ARROWHEAD PHARMACEUTICALS, INC.

Ticker

ARWR

Shares

75.0K

Price per share

$0

Execution date (reported)

Jan 6, 2026

Owned after transaction

176.2K shares

Days from execution to publication

2

What this establishes

Apel Daniel Joseph filed this Form 4 reporting a grant or award of ARWR on Jan 6, 2026. It became public on Jan 8, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Chief Financial Officer

Apel Daniel Josephcik:0002081169

Issuer

ARROWHEAD PHARMACEUTICALS, INC.cik:0000879407

Revision history · 0

No field has changed since this record was first ingested.